Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), will present data from its 15-HMedIdeS-09 Phase 2 single arm study of imlifidase, a first in class IgG cleaving enzyme, in Guillain-Barré Syndrome ...

Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today ...

Fluctuations related to treatment may occur in 5%-15% of patients, corresponding to relapses during the plateau phase or after initiating the recovery phase. In such cases, retreatment may be ...

Anito-cel is partnered with Kite, a Gilead Company. The Phase 2 iMMagine-1 data are from a May 1, 2025 data cutoff date, including all 117 patients with a median follow-up of 12.6 months and a ...

(RTTNews) - Arcellx, Inc. (ACLX), a biotechnology company, Wednesday announced new positive data from its pivotal Phase 2 iMMagine-1 study of anitocabtagene autoleucel (anito-cel), in patients ...

Depressive symptoms rose progressively in the 15 years leading up to dementia diagnosis, with the highest elevations ...

Ciara Freeman, MD, PhD, discusses anito-cel's unique functions and benefits for treating multiple myeloma. In an interview with Targeted Oncology TM, Ciara Freeman, MD, medical oncologist at Moffitt ...

Valneva SE offers exposure to a robust travel vaccine portfolio that includes Ixiaro, Dukoral, and Ixchiq. Read what ...

FDA Meeting for Tanruprubart (formerly ANX005), the First Potential Targeted Therapy for GBS, Scheduled for Second Quarter 2025 Ahead of Planned BLA Submission Open-Label Tanruprubart FORWARD Study ...

"Also, of note, following the positive full results from the 15-HMedIdeS-09 single arm Phase 2 study in Guillain Barre Syndrome (GBS) shared in December 2024, the data is set to be presented at an ...

(Neurology) The phase II PIVOT-HD study of votoplam (PTC518) met its primary endpoint of reducing blood huntingtin protein levels in people with stage 2 and stage 3 Huntington's disease ...